• Proven model: Katalysen’s new Venture Targeter Framework (VTF) has already created a combined 9.5x increase in value on invested capital through recent medtech cases QuTEM and S4DX.
• Deep value: The share is currently trading at a 40% discount to NAV, which Mangold views as unjustified given the company’s traction and low cost base.
• Smart structure: Katalysen co-invests through SPVs and earns upside through value creation – not management fees – ensuring full alignment with partners.
• Focused strategy: The portfolio consists of 23 B2B companies across four tech-driven segments, with a NAV of SEK 138M.
• Experienced team: Founders with decades of entrepreneurial and investment experience lead the company and remain significant shareholders.
• Transformation partner: Positioned as an “investment catalyst,” Katalysen targets companies in special situations and unlocks their potential through hands-on collaboration and structured exits.

‍

Check out the full report if you want to learn more, we found it to provide a rather balanced perspective, highlighting both opportunities as well as areas in which we shall improve: https://lnkd.in/eibv-299